openPR Logo
Press release

Discover the Growth of the Hepatitis A Vaccines Market

01-18-2018 02:05 PM CET | Health & Medicine

Press release from: Transparency Market Research

Hepatitis A is a liver disease caused by hepatitis A virus that can lead to mild to severe illness. The hepatitis A virus (HAV) is spread through direct contact with an infectious person or through ingestion of contaminated food and water. Most patients recover fully from hepatitis A with a lifelong immunity. However, a small number of people with hepatitis A could succumb to the disease.

Rise of hepatitis A infection is linked with poor sanitation & hygiene and lack of safe water. Hepatitis A occurs periodically and in epidemics globally, with a propensity for cyclic reappearances. The hepatitis A virus is one of the common reasons for foodborne infection. An effective and safe vaccine is available to prevent hepatitis A. Safe water supply, food safety, improved sanitation, and hand washing could also be effective ways to combat hepatitis A.

According to the U.S. Department of Health and Human Services, hepatitis A is a vaccine-preventable, communicable disease of the liver caused by the hepatitis A virus (HAV). Antibodies produced in response to hepatitis A infection last through life and protect against recurrence of infection. The best way to prevent hepatitis A is through vaccination. Vaccines available in market are Havrix, Vaqta, and Twinrix. Vaccination is recommended for all children aged 12 months or older, travelers to locations with increased hepatitis A infection, people who inject illegal drugs, those with a blood clotting problem, and anyone with long-term liver disease.

Download Report Brochure @

Hepatitis A vaccine is given in two doses, six months apart. The vaccine also comes in a combination form, containing both hepatitis A and B vaccine, which can be given to persons 18 years or older. This form is given as three doses, over a period of six months or as three doses over one month and a booster dose at 12 months. A dose called immune globulin (IG) can be considered an addition to hepatitis A vaccine for adults, persons with compromised immunity, and persons with chronic liver disease or other chronic medical conditions who are traveling within two weeks.

Based on distribution channel, the global hepatitis A vaccines market can be segmented into hospitals, clinics, and organizations associated with government vaccinations programs. Rise in number of hepatitis A cases is forcing governments and health care organizations to spread awareness about the disease. This drives the global hepatitis A vaccines market. According to the Centers for Disease Control and Prevention, in 2015, a total of 1,390 cases of hepatitis A were reported from 50 states in the U.S. The overall incidence rate in 2015 was 0.4 cases per 100,000 population. Actual acute cases are estimated to be 1.96 times the number of reported cases in any year.

The global hepatitis A vaccines market can be segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Asia Pacific is projected to reflect a high CAGR due to rise in pediatric population and increase in awareness about vaccination. Continuous efforts by market players and national organizations to promote hepatitis A vaccines is likely to drive the market in the developed regions.

According to the WHO, in developing countries with poor sanitary conditions and hygienic practices, around 90.0% children are infected with the hepatitis A virus before the age of 10 years. Government vaccination programs in developing countries propel the global hepatitis A vaccines market. Rise in awareness about hepatitis is also one of the key factors augmenting the market in developing countries.

Pre-Book Full Report @<ype=S

Key players in the global hepatitis A vaccines market include GlaxoSmithKline and Merck & Co., Inc.

About Us

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Contact Us

Transparency Market Research
State Tower,
90 State Street, Suite 700
Albany, NY 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Discover the Growth of the Hepatitis A Vaccines Market here

News-ID: 907345 • Views: 83

More Releases from Transparency Market Research

Wearable EEG Devices Market: Growing incidences of Neurovascular Disorders is Dr …
According to new market research titled 'Wearable EEG Devices Market to 2027 - Global Analysis and Forecasts by Channel and Application.' The global wearable EEG devices market is expected to reach US$ 1,556.35 Mn in 2027 from US$ 745.05 Mn in 2018. The market is projected to grow with a CAGR of 8.7% from 2019-2027. The report provides trends prevailing in the global wearable EEG devices market and the factors
Decentralized Electricity Generation Market - Global Industry Analysis, Share, G …
Global Decentralized Electricity Generation Market: Overview With the increasing installation of smart grids and the rising number of electricity generation resources, the power generation industry has been undergoing a significant change over the recent past. The modification in the grid structure, which permits decentralization of electricity generation, is acting as the main driving force behind the substantial growth of the global market for decentralized electricity generation. The main objective of this research
Global Sucralose Market Outlook In The Developed And Emerging Industry
Sucralose Market Overview Sugar substitute market is witnessing an increasing demand driven by the increasing sales of various sugar substitutes such as natural sweeteners and artificial sweeteners. Sucralose, an artificial sweetener used as a sugar substitute is highly preferred by consumers owing to its zero calorie attribute. Though sucralose is 600 times sweeter than sugar but interestingly it is not identified as the carbohydrate by the human body. Sucralose has its
Flavored Syrup Market - Growth Powered with Latest Development Scenario & Influe …
Flavored Syrup Market Introduction Global syrup market is witnessing a significant demand generated by the food and beverage industry. Consumers' increasing preference for different and personalized flavors in food has driven the syrup manufacturers to produce a wide range of flavored syrups. Flavored syrups contain artificial or natural flavorings mixed along with sugar and water. Obtain Report Details @ Increasing demand of flavored syrups especially among the consumers contributes to the

All 5 Releases

More Releases for Hepatitis

Hepatitis E Therapeutics Pipeline Analysis 2018
Hepatitis E is a liver disease caused by infection due to a virus known as hepatitis E virus (HEV). This disease can cause swelling in liver. Some of the common symptoms are mild fever, feeling of tiredness, feeling sick to stomach, and belly pain. Download the sample report at: The World Health Organization (WHO) estimates released in 2018 stated that, every year, an estimated 20 million HEV infections worldwide, leading to
Hepatitis Drugs Market Opportunity Assessment Study
The global hepatitis drugs market is growing due to increasing incidences of hepatitis and increasing support from government organizations. In addition, the growing geriatric population, and increasing R&D investments on hepatitis research and drug discovery are also driving the growth of the global hepatitis drugs market. Access Detailed Report Summary: The increasing incidences of various types of hepatitis, such as hepatitis B, and hepatitis C are playing a pivotal role in
Global Hepatitis A Vaccine Sales Market Report
In this report, the global Hepatitis A Vaccine market is valued at USD XX million in 2017 and is expected to reach USD XX million by the end of 2025, growing at a CAGR of XX% between 2017 and 2025. Geographically, this report split global into several key Regions, with sales (K Units), revenue (Million USD), market share and growth rate of Hepatitis A Vaccine for these regions, from 2013
Hepatitis B Vaccines Market Growth Analysis 2021
Hepatitis B refers to an infectious disease that is caused by hepatitis B virus. Symptoms of this disease are not visible in initial stages and develop after few weeks only. Hepatitis B virus is transmitted by exposure to infectious blood or body fluids of an infected person. This disease may even occur from the birth. Hepatitis B may be caused by blood transfusions, healthcare setting, sharing razors and dialysis. Hepatitis
Hepatitis Drug Market Hepatitis Drug Clinical Pipeline Report 2023
For Report Sample Contact: or +91-11-47067990 Report Table of Contents 1. Introduction to Hepatitis Disease 1.1 Prologue 1.1.1 History of Hepatitis 1.1.2 Causes of Hepatitis Disease 1.2 Types of Viruses which are Responsible for Hepatitis Disease 2. Global Prevalence of Hepatitis Infection 3. Available Drug Classes for Hepatitis Disease Treatment 3.1 Interferon Alfa Therapy 3.2 Protease Inhibitors Therapy 3.3 Polymerase
Global Hepatitis C Drug Sales Market 2017
In this report, the Global Hepatitis C Drug Market 2017 is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split global into several key Regions, with sales (K Units), revenue (Million USD), market share and growth rate of Hepatitis C Drug for these regions, from 2012